Denver, Colorado (PRWEB) September 16, 2015
CereScan Corporation has published a technical white paper defining the enhanced capabilities of its CereMetrix™ Brain Diagnostics Database. The white paper outlines the four major capabilities now in development to enhance the abilities of CereScan’s reading physicians as well as treating physicians everywhere. These new features will allow for a more accurate diagnosis of brain abnormalities in less time.
The four major areas of development are:
1)The robust clinical workflow ensures consistent, timely, and accurate scan results.
2)The automated Diagnostic Assistance and Intelligent Support system takes the subjectivity out of the diagnostic process and uses quantitative measurements to more accurately assist the doctor in diagnosing complex brain disorders.
3)The in-depth patient repository combines a comprehensive clinical history with current symptomology, and quantitative image data.
4)Finally, the built-in Clinical Trial Support System allows for a comparative analysis between current patients and de-identified patient cohorts to further enhance diagnosis and treatment outcome. This system will also facilitate research projects aimed at examining the efficacy of innovative brain therapies.
CereScan is redefining the standard for brain diagnostics. Click on the link below to read the executive summary.
CereScan combines state-of-the-art SPECT and PET/CT brain imaging technologies with a patient- centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the neurological basis of their conditions. In a variety of legal settings, CereScan provides objective evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit http://www.cerescan.com.